Tag: fixed-duration immunotherapy

Home / fixed-duration immunotherapy

Categories

Glofitamab-gxbm is approved by FDA for selected relapsed or refractory large B-cell lymphomas

July 2023: The Food and Drug Administration gave accelerated approval to glofitamab-gxbm (Columvi, Genentech, Inc.) for relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (...
fixed-duration-immunotherapy

Scan the code